Transaction details
According to a Form 4 filing with the Securities and Exchange Commission, Lenz Therapeutics (NASDAQ: LENZ) Chief Executive Officer Evert B. Schimmelpennink purchased 28,089 shares of the company's common stock on March 27, 2026. The shares were acquired at a weighted average price of $8.9505, within a purchase price range of $8.80 to $9.25, for a total consideration of approximately $251,410.
Market context and valuation note
The acquisition occurred as the stock was trading near its 52-week low of $8.39 and after a 24% decline in the prior week. InvestingPro analysis, cited in the filing context, indicates that LENZ appears undervalued at current market levels when compared to Fair Value estimates, a factor the filing suggests could have influenced the CEO's decision to buy shares.
Post-transaction ownership
Following the March 27 transaction, Schimmelpennink directly holds 77,289 shares of Lenz Therapeutics. The Form 4 filing documents the change in direct ownership resulting from the purchase.
Recent financial results and product rollout
In other company disclosures, Lenz Therapeutics reported fourth-quarter 2025 results that showed a strong cash position and the emergence of initial revenue tied to its new presbyopia treatment, VIZZ. The company also recorded a significant quarterly net loss for that period, which the company attributed to increased operating expenses.
Commercialization of VIZZ formally began in October 2025. The company reported that VIZZ achieved broad availability by mid-fourth quarter 2025, but year-end revenue trends reflect less than a full quarter of adoption - a timing factor the company highlights in reporting its financial results.
Analyst coverage and outlook
H.C. Wainwright reiterated a Buy rating on Lenz Therapeutics and kept a price target of $56.00. The analyst firm noted that the recent commercialization of VIZZ had not yet fully impacted the company’s financial performance because the product had limited adoption time within the quarter assessed.
Research access
For investors seeking additional valuation context, the filing references a Pro Research Report that covers LENZ and more than 1,400 other U.S. equities. That report is presented as a source for deeper analysis of the company’s valuation and other metrics.
This report presents the transaction, recent financial results and analyst commentary as disclosed in company filings and analyst notes.